Current Management of In-Stent Restenosis

被引:4
作者
Giacoppo, Daniele [1 ]
Mazzone, Placido Maria [1 ]
Capodanno, Davide [1 ]
机构
[1] Univ Catania, Dept Surg & Med Surg Specialties, Div Cardiol, Azienda Osped Univ Policlin Rodol San Marco, Via Santa Sofia 78, I-95124 Catania, Italy
关键词
in-stent restenosis; percutaneous coronary intervention; drug-coated balloon; drug-eluting stent; intravascular imaging; DRUG-ELUTING STENT; PACLITAXEL-COATED BALLOON; OPTICAL COHERENCE TOMOGRAPHY; DUAL-ANTIPLATELET THERAPY; PERCUTANEOUS CORONARY INTERVENTION; BIORESORBABLE VASCULAR SCAFFOLDS; RANDOMIZED-TRIAL; INTRAVASCULAR LITHOTRIPSY; CUTTING BALLOON; ARTERY-DISEASE;
D O I
10.3390/jcm13082377
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available strategies, influenced by a complex interplay between clinical and lesion-specific conditions. Given the multiple mechanisms contributing to the development of ISR, proper identification of the underlying substrate, especially by using intravascular imaging, becomes pivotal as it can indicate distinct therapeutic requirements. Among standalone treatments, drug-coated balloon (DCB) angioplasty and drug-eluting stent (DES) implantation have been the most effective. The main advantage of a DCB-based approach is the avoidance of an additional metallic layer, which may otherwise enhance neointimal hyperplasia, provide the substratum for developing neoatherosclerosis, and expose the patient to a persistently higher risk of coronary ischemic events. On the other hand, target vessel scaffolding by DES implantation confers relevant mechanical advantages over DCB angioplasty, generally resulting in larger luminal gain, while drug elution from the stent surface ensures the inhibition of neointimal hyperplasia. Nevertheless, repeat stenting with DES also implies an additional permanent metallic layer that may reiterate and promote the mechanisms leading to ISR. Against this background, the selection of either DCB or DES on a patient- and lesion-specific basis as well as the implementation of adjuvant treatments, including cutting/scoring balloons, intravascular lithotripsy, and rotational atherectomy, hold the potential to improve the effectiveness of ISR treatment over time. In this review, we comprehensively assessed the available evidence from randomized trials to define contemporary interventional treatment of ISR and provide insights for future directions.
引用
收藏
页数:22
相关论文
共 136 条
  • [1] Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial
    Adriaenssens, Tom
    Dens, Jo
    Ughi, Giovanni
    Bennett, Johan
    Dubois, Christophe
    Sinnaeve, Peter
    Wiyono, Stefanus
    Coosemans, Mark
    Belmans, Ann
    D'hooge, Jan
    Vrolix, Mathias
    Desmet, Walter
    [J]. EUROINTERVENTION, 2014, 10 (04) : 439 - 448
  • [2] PCSK9 inhibitors: current status and emerging frontiers in lipid control
    Agnello, Federica
    Mauro, Maria Sara
    Rochira, Carla
    Landolina, Davide
    Finocchiaro, Simone
    Greco, Antonio
    Ammirabile, Nicola
    Raffo, Carmelo
    Mazzone, Placido Maria
    Spagnolo, Marco
    Occhipinti, Giovanni
    Imbesi, Antonino
    Giacoppo, Daniele
    Capodanno, Davide
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2024, 22 (1-3) : 41 - 58
  • [3] Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis - Results of the Restenosis Cutting Balloon Evaluation Trial (RESCUT)
    Albiero, R
    Silber, S
    Di Mario, C
    Cernigliaro, C
    Battaglia, S
    Reimers, B
    Frasheri, A
    Klauss, V
    Auge, JM
    Rubartelli, P
    Morice, MC
    Cremonesi, A
    Schofer, J
    Bortone, A
    Colombo, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (06) : 943 - 949
  • [4] Management of in-stent restenosis
    Alfonso, Fernando
    Coughlan, J. J.
    Giacoppo, Daniele
    Kastrati, Adnan
    Byrne, Robert A.
    [J]. EUROINTERVENTION, 2022, 18 (02) : E103 - U33
  • [5] A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis -: Results of the restenosis intrastent:: Balloon angioplasty versus elective sirolimus-eluting stenting (RIBS-II) trial
    Alfonso, Fernando
    Perez-Vizcayno, Maria-Jose
    Hernandez, Rosana
    Bethencourt, Armando
    Marti, Vicens
    Lopez-Minguez, Jose R.
    Angel, Juan
    Mantilla, Ramon
    Moris, Cesar
    Cequier, Angel
    Sabate, Manel
    Escaned, Javier
    Moreno, Raul
    Bañuelos, Camino
    Suarez, Alfonso
    Macaya, Carlos
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (11) : 2152 - 2160
  • [6] 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents
    Alfonso, Fernando
    Jose Perez-Vizcayno, Maria
    Cuesta, Javier
    Garcia del Blanco, Bruno
    Garcia-Touchard, Arturo
    Ramon Lopez-Minguez, Jose
    Masotti, Monica
    Zueco, Javier
    Cequier, Angel
    Velazquez, Maite
    Moreno, Raul
    Mainar, Vicente
    Dominguez, Antonio
    Moris, Cesar
    Molina, Eduardo
    Rivero, Fernando
    Jimenez-Quevedo, Pilar
    Gonzalo, Nieves
    Fernandez-Perez, Cristina
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (10) : 981 - 991
  • [7] Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis The RIBS VI Study
    Alfonso, Fernando
    Cuesta, Javier
    Jose Perez-Vizcayno, Maria
    Garcia del Blanco, Bruno
    Ramon Rumoroso, Jose
    Bosa, Francisco
    Perez de Prado, Armando
    Masotti, Monica
    Moreno, Raul
    Cequier, Angel
    Gutierrez, Hipolito
    Garcia Touchard, Arturo
    Ramon Lopez-Minguez, Jose
    Zueco, Javier
    Marti, Vicens
    Velazquez, Maite
    Moris, Cesar
    Bastante, Teresa
    Garcia-Guimaraes, Marcos
    Rivero, Fernando
    Fernandez, Cristina
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (18) : 1841 - 1851
  • [8] A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents The RIBS IV Randomized Clinical Trial
    Alfonso, Fernando
    Perez-Vizcayno, Maria Jose
    Cardenas, Alberto
    del Blanco, Bruno Garcia
    Garcia-Touchard, Arturo
    Lopez-Minguez, Jose Ramon
    Benedicto, Amparo
    Masotti, Monica
    Zueco, Javier
    Iniguez, Andres
    Velazquez, Maite
    Moreno, Raul
    Mainar, Vicente
    Dominguez, Antonio
    Pomar, Francisco
    Melgares, Rafael
    Rivero, Fernando
    Jimenez-Quevedo, Pilar
    Gonzalo, Nieves
    Fernandez, Cristina
    Macaya, Carlos
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (01) : 23 - 33
  • [9] Current Treatment of In-Stent Restenosis
    Alfonso, Fernando
    Byrne, Robert A.
    Rivero, Fernando
    Kastrati, Adnan
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (24) : 2659 - 2673
  • [10] Treatment of Coronary In-Stent Restenosis With Bioabsorbable Vascular Scaffolds
    Alfonso, Fernando
    Nuccio, Julio
    Cuevas, Cecilia
    Cardenas, Alberto
    Gonzalo, Nieves
    Jimenez-Quevedo, Pilar
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (25) : 2875 - 2875